Shares of Erasca (NASDAQ: ERAS) slid by more than 11% in morning trading on Friday after the clinical-stage precision oncology company announced the pricing of its public offering of 15.38 million shares of its common stock at a price of $6.50 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The gross proceeds to Erasca from the offering, before deducting the offering expenses, are expected to be around $100 million. The offering is expected to close on December 13.
Moreover, the company also announced an exclusive worldwide license agreement with Novartis (NVS) for naporafenib, a potential drug against cancer.
As a part of this licensing agreement, Erasca will pay Novartis a “one-time upfront cash payment of $20 million and $80 million of shares in Erasca common stock at a price of $6.50 per share. “
Novartis would also be eligible to receive up to $80 million in cash upon the “achievement of regulatory milestones covering two indications in the United States, Europe, and Japan, as well as up to $200 million in cash upon the achievement of sales milestones.” In addition, NVS would also receive a “low single-digit percentage royalty on net sales of naporafenib.”
ERAS stock has dropped more than 50% this year.